Navigation Links
NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance
Date:11/1/2007

ications, including hypoparathyroidism and osteoporosis. NPS is committed to advancing the development of PREOS in hypoparathyroidism where worldwide annual sales could exceed $200 million. NPS is currently reviewing its development and commercialization options for PREOS in osteoporosis and expects to make a decision regarding this indication in the first quarter of 2008.

Third Quarter 2007 Financial Results

NPS reported net income for the third quarter of 2007 of $14.1 million, or $0.28 per diluted share, versus a net loss in the third quarter of 2006 of $21.1 million, or $0.45 per diluted share. The third quarter profit in 2007, versus a loss in the same period of 2006, reflects aggressive expense reduction measures, increased revenues from royalties and product sales, and gains from the sale of fixed assets related to site closures in Salt Lake City and Toronto.

Revenues for the third quarter of 2007 grew 190% to $29.2 million from revenues of $10.1 million in the third quarter of 2006. Increased revenues are primarily the result of higher royalty revenue earned from Amgen on sales of cinacalcet HCl and increased product sales, royalty and milestone revenue earned from Nycomed on sales of Preotact(R).

Research and development expenses for the third quarter of 2007 declined 61% to $5.4 million compared to $13.7 million for the same period of 2006. These changes are primarily due to decreased clinical development activity for PREOS, reductions in personnel, and associated cash and stock compensation, and lower pre-approval manufacturing expenses associated with PREOS, offset by higher pre-approval manufacturing expenses associated with GATTEX.

Selling, general and administrative expenses for the third quarter 2007 declined 23% to $5.7 million compared to $7.5 million for the same period in 2006. These decreases are primarily due to reductions in personnel and associated cash and stock compensation.

Restructuring charges for the
'/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Dec. 15 AstraZeneca (NYSE: ... Virginia (UVa) in Charlottesville, today announced that ... collaboration to enhance development of new treatments ... a secondary focus on peripheral vascular disease ... ,, The collaborative preclinical research projects will ...
(Date:12/15/2009)... 15 The Center for Business ... is pleased to announce the full agenda ... and Reporting Congress . The forum will ... March 16-17, 2010. ,, Over 1,500 senior-level ... attended this premier event since its inception, ...
(Date:12/15/2009)... launch of several innovative new programs to aid cash-strapped ... economic climate. The first is aimed at entrepreneurs ... over a period of 6, 12, 18, or 24 ... The second is aimed at more established businesses ... to 12 month period at discounted rates, and even ...
(Date:12/14/2009)... Joins with State Biotech Leaders to Develop ... and Development while Boosting Rhode Island,s Growing ... PROVIDENCE, R.I., Dec. 14 Several ... research, medicine and biotechnology gathered today at ... the importance of medical innovation in Rhode ...
Breaking Biology Technology:AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 2AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 3CBI Announces the Agenda for Their 6th Annual Pharmaceutical/Biotech Accounting and Reporting Congress 2The Prinz Law Office Launches Innovative New Programs to Aid Cash-Strapped Entrepreneurs and Businesses 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 4
... -- Wisconsin residents would lose their ability to ... in the state under legislation proposed by state Sen. ... he would introduce legislation similar to that he proposed ... original proposal. He expects broad legislative support for the ...
... Wis., has announced that Dick Blick ... RedPrairie DLx Warehouse and RedPrairie DLx Labor at its distribution ... based in Highland Park, Ill., offers more than 30,000 art ... , , Analytical Surveys, Inc., ...
... . and partners Rockwell Collins and the University ... late Wednesday to compete in the $2 million DARPA Grand ... Desert on Saturday, Oct. 8. , , TerraMax completed ... courses at the California Speedway in Fontana, Calif. , ...
Other Biology Technology:Bill would ban computers from landfills 2Bill would ban computers from landfills 3Oshkosh's robotic truck qualifies for DARPA challenge 2
(Date:12/15/2009)... The mouse is a standard laboratory model organism, ... conventional techniques to analyze blood and blood-forming tissues ... of compact and easy-to-use laboratory resources from Cold ... Mouse Hematology features step-by-step protocols for ... blood, bone marrow, and other hematopoietic tissues in ...
(Date:12/14/2009)... that could help wean the nation from oil, would ... gasoline, especially in winter, according to a new study ... both gasoline and E85, a blend of gasoline and ... warm sunny weather than during the cold weather and ... to ozone formation. But E85 produces different byproducts of ...
(Date:12/14/2009)... researchers from the Astrobiology Centre (INTA-CSIC) has shown that ... the formation of the most basic biological molecules can ... to carry out this study, published in the journal ... chemical conditions of the early Earth. , "We have ... solutions it produces hydrogen cyanide, a substance that could ...
Breaking Biology News(10 mins):New source of classical techniques for blood-based studies in the laboratory mouse 2Ethanol-powered vehicles generate more ozone than gas-powered ones 2Ethanol-powered vehicles generate more ozone than gas-powered ones 3Prussian blue linked to the origin of life 2Medco to Present at June 2009 Investor Conferences 48069 1Medco to Present at June 2009 Investor Conferences 48069 2Cant Sleep 3F Try Online Therapy 48067 1Cant Sleep 3F Try Online Therapy 48067 2NEJM study points to new era in hepatitis C treatment 48064 1NEJM study points to new era in hepatitis C treatment 48064 2NEJM study points to new era in hepatitis C treatment 48064 3
... strong support for agriculture and the conservation of Colorado,s and ... Excellence in Soil Stewardship Award presented by the Soil Science ... Coloradan, Senator Salazar grew up on a ranch in Colorado,s ... the land since homesteading. The Senator serves on both the ...
... Canadian and Finnish scientists has identified a protein able to ... in the recognition and the elimination of infectious agents. The ... and Cancer (IRIC) at the Universit de Montral in Canada ... the latest edition of the journal Immunity ...
... that your enemies know your weaknesses best is especially ... have co-evolved: As the predators evolve new strategies for ... Milkweed is the latest example of this response, according ... away from elaborate defenses against specialized caterpillars toward a ...
Other Biology News:Identification of protein able to stimulate production of T-cells 2Milkweed's evolutionary approach to caterpillars: Counter appetite with fast repair 2
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Biology Products: